does FLGR242 have a 19-day half-life?
a half-life belongs to an exact molecule and formulation. the public record does not first establish what FLGR242 is.
verdict: unsupported because identity and PK both fail (identity unresolved / no compound-specific study)
quick answer
no FLGR242-specific concentration-time study supporting 19 days was located. Exact-name biomedical and trial-registry searches found no study, and the broad GLYCLOK patent does not name or characterize FLGR242.
the evidence
the identity problem comes first. (gap)
No verified sequence, structure, characterization package, animal study, human trial, or product-specific PK source was located under the exact name.
a platform patent is not a product study. (contradicted)
The accessible GLYCLOK application describes a broad albumin-binding platform but does not name FLGR242 or report its pharmacokinetics.
purity does not close the gap. (risk)
A purity percentage cannot establish sequence, modification, folding, activity, sterility, or endotoxin burden. No proxy molecule supplies the missing 19-day number.
bottom line
the number cannot be validated before the test article itself is reproducibly identified.
scores
- identity: 0 — no verified sequence or exact structure
- compound PK: 0 — no FLGR242 concentration-time study
- human evidence: 0 — no registered study located
- claim risk: 96 — platform language is being treated as product proof
keep reading
- open FLGR242 entry — full identity-failure record
- growth-hormone category — characterized comparators
- open follistatin entry — do not transfer a different molecule's record
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
